Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors

被引:25
作者
Purshouse, Karin [1 ]
Watson, Robert A. [1 ]
Church, David N. [1 ,2 ,3 ]
Richardson, Charlotte [1 ]
Crane, Gemma [1 ]
Trail, Zoe [4 ]
Sullivan, Mark [5 ]
Roberts, Ian [6 ]
Browning, Lisa [6 ]
Turner, Gareth [6 ]
Parameshwaran, Vishnu [1 ,6 ]
Johnson, Joseph [1 ]
Chitnis, Meenali [1 ]
Protheroe, Andrew [1 ]
Verrill, Clare [6 ]
机构
[1] Oxford Univ Hosp NHS Trust, Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford Ctr Canc Gene Res, Roosevelt Dr, Oxford OX3 7BN, England
[3] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford Ctr Canc Gene Res, Roosevelt Dr, Oxford OX3 7BN, England
[4] Churchill Hosp, Dept Radiol, Oxford, England
[5] Churchill Hosp, Dept Urol, Oxford, England
[6] Oxford Univ Hosp NHS Trust, John Radcliffe Hosp, Dept Cellular Pathol, Oxford, England
关键词
Germ cell tumor; Histopathology review; STAGE-I SEMINOMA; PROGNOSTIC-FACTORS; CANCER; SURVEILLANCE; RELAPSE;
D O I
10.1016/j.clgc.2016.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The importance of specialist histopathology review in determining the tumor prognostic factors required to guide contemporary testicular cancer management is unknown. In a large series from a tertiary center, we found that expert review altered the pathology reports in 27.7% of cases, with a predicted effect on treatment for 6.5% of patients. Thus, specialist histopathology review is essential for the delivery of personalized testicular cancer care. Purpose: Testicular cancers are an uncommon and highly curable group of tumors that are typically managed by specialist multidis.ciplinary teams (MDTs). Although recent guidelines have emphasized the importance of tumor prognostic factors in predicting recurrence and personalizing therapy in early-stage disease, the role of central pathology review in determining these factors is unclear. Patients and Methods: We compared the referral histopathology reports with those obtained after expert central review for all cases reviewed by the UK Thames Valley Cancer Network testicular tumor MDT from August 2004 to September 2012. For cases in which the findings differed, we recorded the effect of the alteration on the estimates of patient prognosis and predicted clinical management using international (European Society of Medical Oncology [ESMO]) and local guidelines. Results: The histopathology reports were altered after central review in 129 of 465 cases (27.7%) referred to the testicular tumor MDT during the study period. These resulted in changes in the estimation of prognosis for 42 patients (9.0% total), with a predicted affect on management according to the ESMO guidelines in 30 cases (6.5%). These proportions were broadly similar for both seminoma and nonseminoma, although the reasons for the discrepancies differed between the 2 (principally errors in categorization of rete testis invasion in seminoma and of lymphovascular invasion in nonseminoma). Changes to the tumor type were uncommon (2 cases). Conclusion: Central MDT review results in frequent, clinically relevant alterations to testicular tumor histopathology reports for testicular tumors. The results of our study demonstrate the importance of specialist MDTs to inform patient centered care and ensure best practice in the management of these uncommon cancers.
引用
收藏
页码:152 / 156
页数:5
相关论文
共 22 条
[1]  
Aggarwal N, 2009, ARCH PATHOL LAB MED, V133, P1985, DOI 10.1043/1543-2165-133.12.1985
[2]   Guidelines on Testicular Cancer: 2015 Update [J].
Albers, Peter ;
Albrecht, Walter ;
Algaba, Ferran ;
Bokemeyer, Carsten ;
Cohn-Cedermark, Gabriella ;
Fizazi, Karim ;
Horwich, Alan ;
Laguna, Maria Pilar ;
Nicolai, Nicola ;
Oldenburg, Jan .
EUROPEAN UROLOGY, 2015, 68 (06) :1054-1068
[3]   Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) [J].
Aparicio, J. ;
Maroto, P. ;
Garcia del Muro, X. ;
Sanchez-Munoz, A. ;
Guma, J. ;
Margeli, M. ;
Saenz, A. ;
Sagastibelza, N. ;
Castellano, D. ;
Arranz, J. A. ;
Hervas, D. ;
Bastus, R. ;
Fernandez-Aramburo, A. ;
Sastre, J. ;
Terrasa, J. ;
Lopez-Brea, M. ;
Dorca, J. ;
Almenar, D. ;
Carles, J. ;
Hernandez, A. ;
Germa, J. R. .
ANNALS OF ONCOLOGY, 2014, 25 (11) :2173-2178
[4]  
Berney D, 2014, STANDARDS DATASETS R
[5]   Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology [J].
Bilici, Ahmet ;
Ozturk, Turkan ;
Turkmen, Esma ;
Odabas, Hatice ;
Cihan, Sener ;
Selcukbiricik, Fatih ;
Erdogan, Bulent ;
Urakci, Zurat ;
Kandemir, Nurten ;
Bayoglu, Ibrahim Vedat ;
Demirci, Umut ;
Duran, Ayse Ocak ;
Sendur, Mehmet Ali Nahit ;
Yavuzer, Dilek ;
Harputluoglu, Hakan ;
Kavgaci, Halil ;
Gumus, Mahmut .
WORLD JOURNAL OF UROLOGY, 2015, 33 (10) :1613-1622
[6]  
Cancer Research UK, 2011, PROST CANC STAT
[7]  
Cancer Research UK, 2013, TEEN YOUNG AD CANC I
[8]   Discrepancy rates in liver biopsy reporting [J].
Colling, Richard ;
Verrill, Clare ;
Fryer, Eve ;
Wang, Lai Mun ;
Fleming, Kenneth .
JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (09) :825-827
[9]   Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours [J].
Cullen, M. .
ANNALS OF ONCOLOGY, 2012, 23 :342-348
[10]   The continued value of central histopathological review of testicular tumours [J].
Delaney, RJ ;
Sayers, CD ;
Walker, MA ;
Mead, GM ;
Theaker, JM .
HISTOPATHOLOGY, 2005, 47 (02) :166-169